Mathieu C, et al. - Experts undertook a comparative analysis of the safety and efficacy of fast-acting insulin aspart (faster aspart) with conventional insulin aspart (IAsp) in adults with type 1 diabetes (T1D). During this study, adults with T1D were randomly allocated to double-blind mealtime faster aspart or IAsp, each with once- or twice-daily insulin detemir. A substantial improvement was achieved in the overall glycaemic control with faster aspart vs IAsp At 52-weeks, consistent with the 26-week study findings. The attainment of an insulin profile closer to physiological insulin secretion with faster aspart translated into lower PPG and HbA1c levels compared with those achieved with IAsp in people with T1D.